

## Recombinant Mouse CD80/B7-1 Protein (His Tag)

**Catalog No.** PKSM040679

**Note:** Centrifuge before opening to ensure complete recovery of vial contents.


### Description

<b>Synonyms</b>	T-lymphocyte activation antigen CD80;Activation B7-1 antigen;B7;CD80;Cd28l;Ly-53;Ly53;MIC17;TSA1
<b>Species</b>	Mouse
<b>Expression Host</b>	HEK293 Cells
<b>Sequence</b>	Met 1-Lys 245
<b>Accession</b>	Q00609-1
<b>Calculated Molecular Weight</b>	25.1 kDa
<b>Tag</b>	C-His
<b>Bioactivity</b>	Measured by its ability to bind recombinant mouse CD28 in a functional ELISA.

### Properties

<b>Purity</b>	> 97 % as determined by reducing SDS-PAGE.
<b>Endotoxin</b>	< 1.0 EU per µg of the protein as determined by the LAL method.
<b>Storage</b>	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
<b>Shipping</b>	This product is provided as lyophilized powder which is shipped with ice packs.
<b>Formulation</b>	Lyophilized from sterile PBS, pH 7.4 Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
<b>Reconstitution</b>	Please refer to the printed manual for detailed information.

### Data



> 97 % as determined by reducing SDS-PAGE.

### Background

The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells,

### For Research Use Only

macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.